# Study of Disulfiram to Reduce Myeloid Immunosuppression and Steroid Dependence in Resectable High Grade Glioma

> **NCT07719127** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Case Comprehensive Cancer Center** · enrollment: 20 (estimated)

## Conditions studied

- Brain (Nervous System) Cancers

## Interventions

- **DRUG:** Disulfiram (DSF)

## Key facts

- **NCT ID:** NCT07719127
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2027-12-17
- **Final completion:** 2027-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07719127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07719127, "Study of Disulfiram to Reduce Myeloid Immunosuppression and Steroid Dependence in Resectable High Grade Glioma". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07719127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*